Compare FIVE & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVE | IONS |
|---|---|---|
| Founded | 2002 | 1989 |
| Country | United States | United States |
| Employees | 24600 | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.9B |
| IPO Year | 2012 | 1996 |
| Metric | FIVE | IONS |
|---|---|---|
| Price | $216.71 | $75.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 22 |
| Target Price | ★ $225.95 | $90.14 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 03-18-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.65 | 21.71 |
| EPS | ★ 6.47 | N/A |
| Revenue | ★ $4,764,147,000.00 | N/A |
| Revenue This Year | $14.40 | N/A |
| Revenue Next Year | $9.41 | $76.97 |
| P/E Ratio | $34.78 | ★ N/A |
| Revenue Growth | ★ 22.90 | N/A |
| 52 Week Low | $60.81 | $27.57 |
| 52 Week High | $238.40 | $86.74 |
| Indicator | FIVE | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 44.98 | 51.20 |
| Support Level | $208.50 | $69.05 |
| Resistance Level | $233.42 | $75.60 |
| Average True Range (ATR) | 8.87 | 2.36 |
| MACD | -1.40 | 0.66 |
| Stochastic Oscillator | 17.86 | 77.26 |
Five Below Inc is a specialty value retailer offering a broad range of trend-right, high-quality products loved by the kid and the kid in all of customers. The Company's edited assortment of products includes select brands and licensed merchandise. The Company also sells its merchandise on the internet, through the Company's e-commerce website and mobile app, offering home delivery and the option to buy online and pick up in store. Additionally, the Company sells merchandise through on-demand third-party delivery services to enable its customers to shop online and receive convenient delivery. It derives revenue from sales of the Company's merchandise to customers.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).